Mergers & AcquisitionsBy The Online Investor Staff, updated Thu., Feb. 27, 3:43 PM
|This Slide: #63 of 100|
Slide #63. Roche — Promedior, Inc.
Promedior, Inc. today announced the successful completion of its previously announced sale to Roche (SIX: RO, ROG; OTCQX: RHHBY). With this acquisition, Roche obtained full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151. Under the terms of the merger agreement, Roche made an upfront cash payment of USD 390 million, with additional contingent payments of up to USD 1 billion to be made based on the achievement of certain predetermined development, regulatory and commercial milestones.
Hold (2.00 out of 4)
(ranked lower than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite